Technical Analysis for BPMC - Blueprint Medicines Corporation
Grade | Last Price | % Change | Price Change |
---|---|---|---|
![]() |
75.26 | -1.09% | -0.83 |
BPMC closed down 1.09 percent on Tuesday, February 19, 2019, on 71 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Feb 20
ADX | Long-Term | Intermediate-Term | Short-Term |
---|---|---|---|
Strong | Up | Up | Up |
See historical BPMC trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Feb 19 | Inside Day | Range Contraction | 0.00% |
Feb 19 | Overbought Stochastic | Strength | 0.00% |
Feb 15 | Pocket Pivot | Bullish Swing Setup | -1.09% |
Feb 15 | Overbought Stochastic | Strength | -1.09% |
Feb 14 | Stochastic Reached Overbought | Strength | 0.83% |
Feb 14 | Overbought Stochastic | Strength | 0.83% |
Feb 12 | 180 Bullish Setup | Bullish Swing Setup | 1.06% |
Feb 11 | MACD Bearish Signal Line Cross | Bearish | 3.76% |
Feb 8 | Hammer Candlestick | Bullish | 2.90% |
Feb 8 | 1,2,3 Pullback Bullish | Bullish Swing Setup | 2.90% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-20
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Cell Biology Cell Signaling Tyrosine Kinase Receptors Protein Kinase Inhibitor Mastocytosis Tyrosine Kinase Gastrointestinal Stromal Tumor Myeloproliferative Neoplasm Rare Genetic Disease Rare Genetic Diseases Systemic Mastocytosis
Biopharmaceutical Cancer Cell Biology Cell Signaling Tyrosine Kinase Receptors Protein Kinase Inhibitor Mastocytosis Tyrosine Kinase Gastrointestinal Stromal Tumor Myeloproliferative Neoplasm Rare Genetic Disease Rare Genetic Diseases Systemic Mastocytosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength | |||
Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. |
See more BPMC news...
Indicators
Indicator | Value |
---|---|
52 Week High | 109.0 |
52 Week Low | 44.58 |
Average Volume | 323,888 |
200-Day Moving Average | 67.6838 |
50-Day Moving Average | 63.1018 |
20-Day Moving Average | 71.8705 |
10-Day Moving Average | 73.884 |
Average True Range | 2.4907 |
ADX | 38.06 |
+DI | 27.6851 |
-DI | 9.5041 |
Chandelier Exit (Long, 3 ATRs ) | 69.26789999999999 |
Chandelier Exit (Short, 3 ATRs ) | 72.87210000000001 |
Upper Bollinger Band | 77.4332 |
Lower Bollinger Band | 66.3078 |
Percent B (%b) | 0.8 |
BandWidth | 15.479787 |
MACD Line | 3.2912 |
MACD Signal Line | 3.4378 |
MACD Histogram | -0.1466 |
Fundamentals | Value |
---|---|
Market Cap | 2.95 Billion |
Num Shares | 39.1 Million |
EPS | -3.12 |
Price-to-Earnings (P/E) Ratio | -24.12 |
Price-to-Sales | 103.31 |
Price-to-Book | 7.06 |
PEG Ratio | 0.00 |
Dividend | 0.00 |
Dividend Yield | 0.00% |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 77.78 | ||||
Resistance 3 (R3) | 77.90 | 77.17 | 77.36 | ||
Resistance 2 (R2) | 77.17 | 76.53 | 77.12 | 77.22 | |
Resistance 1 (R1) | 76.22 | 76.14 | 75.86 | 76.10 | 77.08 |
Pivot Point | 75.49 | 75.49 | 75.31 | 75.44 | 75.49 |
Support 1 (S1) | 74.54 | 74.85 | 74.18 | 74.42 | 73.44 |
Support 2 (S2) | 73.81 | 74.46 | 73.76 | 73.30 | |
Support 3 (S3) | 72.86 | 73.81 | 73.16 | ||
Support 4 (S4) | 72.74 |